Skip to main content
TrimSoMoEverything GLP-1, in one place
FDA Regulatory Enforcement Record

www.buynetmeds.com

Has www.buynetmeds.com received an FDA warning letter? Yes. FDA issued a warning letter dated June 12, 2025 concerning products containing semaglutide.

Letter facts

Letter date
June 12, 2025 (2025-06-12)
Issuing office
Center for Drug Evaluation and Research (CDER)
Products named
Tapentadol (Asmanol 100mg)Tapentadol (Aspadol 50mg/75mg/100mg)Tapentadol (Etadol 100mg)Tapentadol (Noosanta 100mg)Tapentadol (Rin Tapenta 50mg)Tapentadol (Tapaday 50mg/100mg)Tapentadol (Tapal 100mg / Tapal-ER 100mg)Tapentadol (Tapedac 100mg)Tapentadol (Tapenax ER 50mg)Tapentadol (Tapfree ER 100mg)Tapentadol (Tapidol 50mg/100mg)Tapentadol (Tapsmart 100mg)Tapentadol (Topcynta 50mg/100mg)Tapentadol (Tprexadol 100mg)Tapentadol (Tydol 50mg/100mg)Tapentadol (Typendol 100mg)Tapentadol (Yenta 100mg)Semaglutide (Rybelsus 3mg/7mg/14mg tablets)Semaglutide (Semaglutida Tabletas)Semaglutide 0.25 mg Injection (Fitaro 0.25)Semaglutide 0.5 mg Injection (Fitaro 0.5)Semaglutide 1 mg Injection (Fitaro 1)Semaglutide 1.7 mg Injection (Fitaro 1.7)Semaglutide 2.4 mg Injection (Fitaro 2.4)
Violation categories
Unapproved new drugMisbranding

Understanding these violation categories

Unapproved new drug

FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.

Misbranding

FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.

Factual Violation Summary

FDA says the website introduces into interstate commerce unapproved and misbranded semaglutide drug products, including injectable versions.

Active Drug Ingredients

Statutory Citations & Specific Allegations

  • Unapproved new drugs
  • Misbranded drugs
  • Failure to bear adequate directions for use
  • Unlawful sale of prescription drugs to U.S. consumers over the Internet

More letters about Retatrutide

Recent FDA warning letters concerning Retatrutide:

Similar violations (Unapproved new drug)

Recent warning letters with related regulatory findings:

Regulatory Compliance & Editorial Standard:

The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.

Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.